Josamycin
CAS 16846-24-5
Josamycin (CAS 16846-24-5) is a Phase 3 pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 13174.603174603175 nM | 63 | - |
| - | MIC | 98.014042 ug.mL-1 | 50 | - |
| - | IC50 | 13717.539999999999 nM | 2 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Josamycin used for in pharmaceutical contexts?
Josamycin (CAS 16846-24-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Josamycin?
No adverse-event association or SIDER side-effect rows are rendered for Josamycin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Josamycin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Ammonium Methacrylate with EU status "permitted".
What clinical phase is Josamycin in?
Josamycin is rendered with ChEMBL max phase 3.